This Day On The Street
Continue to site
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Two China Pharma Plays

At GeoInvesting, we have been tracking Tianyin Pharmaceuticals (TPI - Get Report) for some time now.

Our largest hang-up had been with the potential dilution from "in-the-money" warrants. Although the company's fiscal June 2010 net income guidance of $11.3 million represents a 43.0% increase from the fiscal 2009 reported net income of $7.9 million, the increase in shares poses some uncertainty regarding the near term EPS growth scenario, which depends upon the share price and the Treasury method of accounting for these warrants under GAAP. (Tianyin reported 32 cents per share for its 2009 fiscal year, based on 24.8 million shares.)

Having said that, on Dec. 3, Tianyin issued fiscal 2011 net income guidance of $19.6 million, implying earnings per share figure of 50 cents, fully taxed. Combine this with an overall positive outlook, a very accomplished management team, cash available to make potential future acquisitions, and the TPI story begins to gain strength.

With a vast product portfolio, the company appears poised to achieve consistent long-term growth. Tianyin currently has 39 products and a solid pipeline of 17 pharmaceutical products pending SFDA approval. The rapid pace at which TPI has obtained SFDA approval has been impressive -- 12 during the past 12 months. This bodes well for quick pipeline revenue generation and market penetration through an extensive distribution channel with full provincial coverage.

The company is also aggressively targeting the macrolide antibiotics market where it sees a significant growth opportunity. Growth should receive an additional boost from the expansion of its manufacturing capacity, which increased approximately 300% for solid dosage forms and can support annual revenues in excess of $100 million.
1 of 3

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Options Profits

Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • Actionable options commentary and news
  • Real-time trading community
SYM TRADE IT LAST %CHG
BSPM $0.68 0.00%
TPI $0.24 0.00%
AAPL $112.92 0.00%
FB $89.73 0.00%
GOOG $637.61 0.00%

Markets

Chart of I:DJI
DOW 16,654.77 +369.26 2.27%
S&P 500 1,987.66 +47.15 2.43%
NASDAQ 4,812.7080 +115.1720 2.45%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs